References
- Aithal GP, Day CP. (2007). Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563–75
- Ashton JC. (2007). Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 8:373–84
- Baba A, Yoshioka T. (2009). Structure-activity relationships for degradation reaction of 1-beta-o-acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions. Chem Res Toxicol 22:158–72
- Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293–301
- Herkenham M, Lynn AB, Little MD, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–6
- Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
- International Conference on Harmonization. (2009) M3(R2): Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Available from: http://private.ich.org/cache/compo/502-272-1.html [last accessed 19 Nov 2012]
- Isin EM, Elmore CS, Nilsson GN, et al. (2012). Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol 25:532–42
- Jolivette LJ, Ward KW. (2005). Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 94:1467–83
- Leleu-Chavain N, Body-Malapel M, Spencer J, et al. (2012). Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. Curr Med Chem 19:3457–74
- Mailleux P, Vanderhaeghen JJ. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655–68
- Moldeus P, Hogberg J, Orrenius S. (1978). Isolation and use of liver cells. Methods Enzymol 52:60–71
- Munro S, Thomas KL, Abu-Shaar M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–5
- Nishibe Y, Hirata M. (1993). Effect of phenobarbital and other model inducers on cytochrome P450 isoenzymes in primary culture of dog hepatocytes. Xenobiotica 23:681–92
- Odan M, Ishizuka N, Hiramatsu Y, et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg Med Chem Lett 22:2803–6
- Ong PY. (2009). Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 14:165–79
- Penner N, Xu L, Parakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513–31
- Tang W. (2007). Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 3:407–20
- U.S. FDA, United States Food and Drug Administration Guidance for Industry, Safety testing of drug metabolites, February 2008. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065014.htm [last accessed 19 Nov 2012]
- Vree TB, van der Ven AJ. (1999). Clinical consequences of the biphasic elimination kinetics for the diuretic effect of frosemide and its acyl glucuronide in humans. J Pharm Pharmacol 51:239–48
- Walker D, Brady J, Dalvie D, et al. (2009). A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 22:1653–62